Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
- PMID: 33928217
- PMCID: PMC7990127
- DOI: 10.1093/abt/tby002
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
Abstract
The targeting of surface antigens expressed on tumor cells by monoclonal antibodies (mAbs) has revolutionized cancer therapeutics. One mechanism of action of antibody-based immunotherapy is the activation of immune effector cells to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). This review will summarize the process of ADCC, its important role in the efficacy of mAb therapy, how to measure it, and finally future strategies for antibody design that can take advantage of it to improve clinical performance.
Keywords: ADCC; Fc glycosylation; FcγR; immunotherapy; monoclonal antibody.
© The Author(s) 2018. Published by Oxford University Press on behalf of Antibody Therapeutics.
References
-
- Adams, G, Weiner, L. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23: 1147–57. - PubMed
-
- Moller, E. Contact-induced cytotoxicity by lymphoid cells containing foreign isoantigens. Science 1965; 147: 873–9. - PubMed
-
- MacLennan, ICM, Loewi, G, Harding, B. The role of immunoglobulins in lymphocyte-mediated cell damage, in vitro. I. Comparison of the effects of target cell specific antibody and normal serum factors on cellular damage by immune and non-immune lymphocytes. Immunology 1970; 18: 397–404. - PMC - PubMed
-
- Teillaud, J. Antibody-dependent cellular cytotoxicity (ADCC). Encyclopedia of Life Sciences. 2012, 10.1002/9780470015902.a0000498.pub2. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources